- Home
- HUDI vs CLRB Comparison
HUDI vs CLRB Comparison
Compare HUDI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUDI
- CLRB
- Stock Information
- Founded
- HUDI 1998
- CLRB 2002
- Country
- HUDI China
- CLRB United States
- Employees
- HUDI N/A
- CLRB N/A
- Industry
- HUDI Steel/Iron Ore
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- HUDI Industrials
- CLRB Health Care
- Exchange
- HUDI Nasdaq
- CLRB Nasdaq
- Market Cap
- HUDI 15.7M
- CLRB 17.5M
- IPO Year
- HUDI 2021
- CLRB N/A
- Fundamental
- Price
- HUDI $1.44
- CLRB $6.17
- Analyst Decision
- HUDI
- CLRB Hold
- Analyst Count
- HUDI 0
- CLRB 2
- Target Price
- HUDI N/A
- CLRB N/A
- AVG Volume (30 Days)
- HUDI 2.5M
- CLRB 83.9K
- Earning Date
- HUDI 08-06-2025
- CLRB 11-17-2025
- Dividend Yield
- HUDI N/A
- CLRB N/A
- EPS Growth
- HUDI N/A
- CLRB N/A
- EPS
- HUDI N/A
- CLRB N/A
- Revenue
- HUDI $66,566,370.00
- CLRB N/A
- Revenue This Year
- HUDI N/A
- CLRB N/A
- Revenue Next Year
- HUDI N/A
- CLRB N/A
- P/E Ratio
- HUDI N/A
- CLRB N/A
- Revenue Growth
- HUDI N/A
- CLRB N/A
- 52 Week Low
- HUDI $1.06
- CLRB $4.11
- 52 Week High
- HUDI $5.46
- CLRB $66.60
- Technical
- Relative Strength Index (RSI)
- HUDI 52.04
- CLRB 65.13
- Support Level
- HUDI $1.35
- CLRB $5.30
- Resistance Level
- HUDI $1.46
- CLRB $5.79
- Average True Range (ATR)
- HUDI 0.10
- CLRB 0.39
- MACD
- HUDI -0.02
- CLRB 0.06
- Stochastic Oscillator
- HUDI 29.29
- CLRB 76.19
About HUDI Huadi International Group Co. Ltd.
Huadi International Group Co Ltd is a manufacturer of industrial stainless steel seamless pipes and tubes products. Its products are used in the oil & gas transmission, chemistry engineering, food processing, medical devices, aeronautics and astronautics, boiler, irrigation works construction, automobile and naval architecture, paper mill and mechanical industries. Company generates revenue from Sales of steel piping products. Products are exported to the United States, Mexico, Thailand, Singapore, Argentina, Taiwan, India, the Philippines, UAE and Canada. Geographically, majority revenue is generated from China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.